---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-130482"
form_type: "8-K"
ticker: "NRXP"
cik: "0001719406"
company_name: "NRX Pharmaceuticals, Inc."
filed_at: "2023-12-29T23:59:59+00:00"
generated_at: "2026-06-07T05:56:47.017753+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# NRx Pharmaceuticals shareholders approve share increase, elect director at 2023 annual meeting

## Summary
- Elected Janet Rehnquist as Class II director: 43.7M votes for, 0.5M withheld.
- Approved amendment to 2021 Omnibus Plan: share pool raised from 6,713,608 to 8,713,608 shares; 29.7M for, 13.5M against.
- Ratified Salberg & Company as independent auditor for FY2023: 42.1M for, 1.9M against.
- Advisory 'say-on-pay' approved (32.0M for, 11.4M against); board set future advisory votes on exec compensation to annual.

## SEC filing metadata
- accession: 0001104659-23-130482
- form_type: 8-K
- ticker: NRXP
- cik: 0001719406
- company_name: NRX Pharmaceuticals, Inc.
- filed_at: 2023-12-29T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/tm2333890d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-130482
- JSON: https://secwatch.observer/filing/0001104659-23-130482.json
- Plain text: https://secwatch.observer/filing/0001104659-23-130482.txt

## Key facts
- Shareholder Votes
  NRX Pharmaceuticals, Inc. shareholders approved Advisory vote on frequency of future advisory votes on executive compensation.
  - Proposal: say on pay frequency
  - Outcome: passed
  source text: The Company’s stockholders approved, on an advisory basis, the frequency of holding an advisory vote on executive compensation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm
- Shareholder Votes
  NRX Pharmaceuticals, Inc. shareholders approved Advisory vote on compensation of named executive officers.
  - Proposal: say on pay
  - Outcome: passed
  source text: The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as set forth in the Proxy Statement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm
- Shareholder Votes
  NRX Pharmaceuticals, Inc. shareholders approved Approval of the Plan Amendment.
  - Outcome: passed
  source text: The Company’s stockholders approved the Plan Amendment.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm
- Shareholder Votes
  NRX Pharmaceuticals, Inc. shareholders approved Ratification of Salberg & Company, P.A. as independent auditors for fiscal year 2023 at the 2023-12-31 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2023-12-31
  source text: The Company’s stockholders ratified the selection of Salberg & Company, P.A. as the Company’s independent auditors for the fiscal year ending December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm
- Shareholder Votes
  NRX Pharmaceuticals, Inc. shareholders approved Election of Janet Rehnquist as a Class II director.
  - Proposal: director election
  - Outcome: passed
  source text: The Company’s stockholders duly elected Janet Rehnquist to serve as a Class II member of the Company’s board of directors until the 2026 Annual Meeting or until the appointment, election, and qualification of her successor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1719406/000110465923130482/0001104659-23-130482-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.